INDP · Why this verdict
Why Indaptus Therapeutics (INDP) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine classifies the stock as speculative given an 85% drawdown from its 52-week high in a binary biotechnology industry, reflecting extreme downside already realized. Suitability rationale | If this recovery setup holds, the stock should stabilize without making new lows over the next 12 months. | →Stable |
| CounterAn 85% drawdown in binary biotech frequently signals a failed or de-risked clinical program, and stocks at this stage often continue declining toward zero rather than recovering. | ||
Quality notes show the company is cash-burning with negative free cash flow and a weak Piotroski F-Score of 2 out of 9, pulling the quality score to 2.0, below the engine's 4.0 floor. Quality breakdown | If this quality concern holds, the Piotroski F-Score should remain at 2 out of 9 or lower over the next 12 months. | →Stable |
| CounterClinical-stage biotechs are structurally expected to burn cash and score poorly on traditional quality metrics, so this reading may reflect business stage rather than incremental risk. | ||
Warnings flag a momentum score of 2.8 against a 4.5 threshold, confirming weak and deteriorating price momentum even as the 200-day moving average remains flat. Warnings | If this momentum breakdown is real, the score should remain below 4.5 over the next 12 months. | →Stable |
| CounterMomentum gate failures on deeply oversold biotech stocks are lagging signals that can persist even as the stock approaches a bottom, offering little predictive value for future direction. | ||
The company's trailing four quarters show a mixed 2-beat, 2-miss record with an average surprise of -39.6%, and no confirmed next earnings date, leaving limited near-term visibility into results. Earnings | If this uncertainty is warranted, the company should continue lacking a confirmed near-term earnings catalyst. | →Stable |
| CounterEarnings surprises for a clinical-stage biotech with minimal revenue are driven largely by R&D expense timing rather than commercial execution, making the beat/miss framing only loosely connected to the actual investment thesis. | ||
Risk components show short interest and days-to-cover both scored at the high end of the range (9.8 and 10.0 respectively out of 10), indicating substantial bearish positioning relative to trading volume. Risk | If this bearish positioning is warranted, the short interest score should remain elevated over the next 12 months. | →Stable |
| CounterElevated short interest and days-to-cover on a heavily shorted, deeply depressed biotech can also set up a sharp short squeeze that drives the price higher independent of fundamentals. | ||
The engine classifies the stock as speculative given an 85% drawdown from its 52-week high in a binary biotechnology industry, reflecting extreme downside already realized.
→StableSuitability rationale
- Expectation
- If this recovery setup holds, the stock should stabilize without making new lows over the next 12 months.
CounterAn 85% drawdown in binary biotech frequently signals a failed or de-risked clinical program, and stocks at this stage often continue declining toward zero rather than recovering.
Quality notes show the company is cash-burning with negative free cash flow and a weak Piotroski F-Score of 2 out of 9, pulling the quality score to 2.0, below the engine's 4.0 floor.
→StableQuality breakdown
- Expectation
- If this quality concern holds, the Piotroski F-Score should remain at 2 out of 9 or lower over the next 12 months.
CounterClinical-stage biotechs are structurally expected to burn cash and score poorly on traditional quality metrics, so this reading may reflect business stage rather than incremental risk.
Warnings flag a momentum score of 2.8 against a 4.5 threshold, confirming weak and deteriorating price momentum even as the 200-day moving average remains flat.
→StableWarnings
- Expectation
- If this momentum breakdown is real, the score should remain below 4.5 over the next 12 months.
CounterMomentum gate failures on deeply oversold biotech stocks are lagging signals that can persist even as the stock approaches a bottom, offering little predictive value for future direction.
The company's trailing four quarters show a mixed 2-beat, 2-miss record with an average surprise of -39.6%, and no confirmed next earnings date, leaving limited near-term visibility into results.
→StableEarnings
- Expectation
- If this uncertainty is warranted, the company should continue lacking a confirmed near-term earnings catalyst.
CounterEarnings surprises for a clinical-stage biotech with minimal revenue are driven largely by R&D expense timing rather than commercial execution, making the beat/miss framing only loosely connected to the actual investment thesis.
Risk components show short interest and days-to-cover both scored at the high end of the range (9.8 and 10.0 respectively out of 10), indicating substantial bearish positioning relative to trading volume.
→StableRisk
- Expectation
- If this bearish positioning is warranted, the short interest score should remain elevated over the next 12 months.
CounterElevated short interest and days-to-cover on a heavily shorted, deeply depressed biotech can also set up a sharp short squeeze that drives the price higher independent of fundamentals.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Indaptus Therapeutics is a deeply speculative biotech following an 85% drawdown, with cash-burning fundamentals below the engine's quality floor, confirmed negative momentum, and heavy short positioning all pointing to elevated risk despite the stock's already-depressed valuation.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.0 |
| FCF quality | 0.0 |
| Moat | 3.8 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.8 |
| MACD | 1.3 |
| OBV | 1.0 |
| MA position | 5.0 |
| Volume | 0.0 |
- ▸Uptrend pullback (RSI 37) - buy opportunity
- ▸Volume distribution (falling OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| erm sentiment | 5.0 |
Insider
5.1/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.2 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.2 |
| support resistance | 7.3 |
| 52w position | 0.0 |
Risk (lower is worse)
6.6/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 9.8 |
| days to cover | 10.0 |
| volatility | 0.0 |
| beta | 6.5 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.8/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.0<4.5
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -86% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Risk (lower is worse) at 6.6 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.0<4.5.
The strongest dimensions are Risk (lower is worse) at 6.6, Insider at 5.1, and Value at 5.0; the weakest are Quality at 2.0, Catalyst at 2.8, and Momentum at 3.0. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Deep Drawdown Speculative Setup
Trip ifThe stock makes a new 52-week low, extending the drawdown to more than 90% from the prior high.
- P2Quality Below Floor Cash Burn
Trip ifPiotroski F-Score rises above 4 out of 9 for 2 consecutive quarters.
- P3Momentum Breakdown
Trip ifMomentum score rises above 4.5 for 2 consecutive quarters.
- P4Mixed Earnings No Near Term Catalyst
Trip ifEPS surprise rises above 0% at the next confirmed reported quarter.
- P5High Short Interest Days To Cover
Trip ifShort interest score falls below 6.0 out of 10 for 2 consecutive quarters.